此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

LiveWell mBC 试点随机对照试验

2026年11月13日 更新者:Kelly Hyland、Medical University of South Carolina

LiveWell mBC:针对转移性乳腺癌女性群体的适应性辩证行为疗法技能训练项目试点测试

In this pilot randomized controlled trial, women with metastatic breast cancer and at least mild distress (N=48) will be randomized to receive LiveWell mBC, a group-based adapted Dialectical Behavioral Therapy (DBT) Skills Training protocol, or Usual Care. The investigators will evaluate feasibility, acceptability, and preliminary efficacy of LiveWell to reduce distress (primary outcome) and improve psychological well-being, symptom burden, and quality of life (secondary outcomes).

研究概览

详细说明

Participants will be randomized 2:1 to receive LiveWell mBC, an adapted DBT Skills Training intervention delivered to small groups of women with mBC via telehealth, or usual care. LiveWell mBC involves orientation + an 8-session skills training protocol of mindfulness, emotion regulation, distress tolerance and interpersonal effectiveness.

Participants will complete self-report measures at baseline, mid-intervention (Week 5), post-intervention (Week 11) and 1 month post-intervention (Week 15). It is hypothesized that: 1) RCT methods will demonstrate evidence of feasibility (>70% overall retention rate, >70% LiveWell mBC completion rate); 2) RCT methods will demonstrated evidence of acceptability (>50% enrollment rate, >80% participant satisfaction); and 3) LiveWell participants will demonstrate reductions in distress (primary outcome) compared to Usual Care at 11-week follow-up.

研究类型

介入性

注册 (估计的)

48

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Benjamin Axelrod
  • 电话号码:843-876-2645
  • 邮箱:axelrod@musc.edu

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  1. identify as female
  2. be diagnosed with metastatic (AJCC stage IV) breast cancer
  3. be receiving care for metastatic breast cancer at Hollings Cancer Center
  4. endorse >3 out of 10 on the NCCN distress thermometer over the past week plus at least one emotional concern on the problem checklist
  5. be > 18 years of age
  6. be able to understand, speak, and read English
  7. be able to provide informed consent.

Exclusion Criteria:

  1. reported or suspected cognitive impairment
  2. presence of untreated serious mental illness (e.g., schizophrenia) indicated by the medical chart or treating oncologist
  3. expected survival <6 months, as indicated by a hospice referral

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
无干预:Usual Care

Will receive a handout with general support resources available at Hollings Cancer Center.

实验性的:LiveWell mBC: A Group-Based Adapted Dialectical Behavioral Therapy Skills Training Program

Will receive 9 telehealth-delivered small group (6-8 participants) sessions (orientation + 8 session DBT skills training protocol) co-facilitated by two skills trainers. Sessions will be 90 minutes each and delivered approximately weekly. Sessions will teach skills from dialectical behavioral therapy (e.g., mindfulness, distress tolerance, emotion regulation, interpersonal effectiveness) adapted for patients with metastatic breast cancer. Sessions follow a standardized structure, including 1) mindfulness practice, 2) home practice and diary card review, 3) learning and practicing new skills, and 4) closing ritual. Participants will have access to a resource library of skills training videos and mindfulness recordings.

LiveWell mBC: A Group-Based Adapted Dialectical Behavioral Therapy Skills Training Program

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
PROMIS Depression Short Form (8a)
大体时间:Baseline (week 0), post-intervention (week 11), and 1-month follow-up (week 15)

Depression will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression (8 items) Short Form Scale. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater depressive symptomology.

Baseline (week 0), post-intervention (week 11), and 1-month follow-up (week 15)
PROMIS Anxiety Short Form (7a)
大体时间:Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

Anxiety will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety (7 items) Short Form Scale. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater anxiety symptomology.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

次要结果测量

结果测量
措施说明
大体时间
Intolerance of Uncertainty Scale - Short Form (IUS-12)
大体时间:Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The 12-item Intolerance of Uncertainty Scale (IUS) Short Form will be used to measure emotional, cognitive, and behavioral reactions to uncertain situations. The IUS has a score range of 12-60, where a higher score indicates greater intolerance of uncertainty.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
Peace, Equanimity, and Acceptance in the Cancer (PEACE) - Peaceful Acceptance of Illness Subscale
大体时间:Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The 5-item Peace, Equanimity, and Acceptance in the Cancer (PEACE) - Peaceful Acceptance of Illness Subscale will be used to assess patient-reported acceptance, inner peace, and tranquility in the context of cancer. The subscale has a score range of 5-20, where a higher score indicates greater peaceful acceptance of illness.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
PROMIS Positive Affect Short Form (15a)
大体时间:Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The PROMIS Positive Affect Short Form 15a will be used to assess patient-reported positive emotions and well-being over the past 7 days. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater positive affect.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
Difficulty in Regulating Emotions Scale (DERS-18)
大体时间:Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)

The DERS-18 will be used to assess emotion dysregulation. The DERS-18 has a score range of 18-80, where a higher score indicates greater difficulty with regulating emotions.

Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
Cognitive and Affective Mindfulness Scale-Revised (CAMS-R)
大体时间:Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)

The 10-item Cognitive and Affective Mindfulness Scale-Revised will be used to assess patient-reported mindfulness qualities, including present-moment awareness, acceptance, and attention. The CAMS-R has a score range of 10-40, where a higher score indicates greater mindfulness.

Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
DBT Ways of Coping Checklist (DBT-WCCL) - DBT Skills Subscale (DSS)
大体时间:Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The DBT Ways of Coping Checklist (DBT-WCCL) -DBT Skills Subscale (DSS) will be used to assess patient-reported frequency of skill use to manage difficult situations. The DBT-WCCL has a score range of 0 to 4, where a higher score indicates greater DBT skill use.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
NCI Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (NCI-PRO-CTCAE)
大体时间:Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The NCI-PRO-CTCAE will be used to assess patient-reported symptom frequency, severity, and interference related to breast cancer and its treatment. Items are rated on a 5-point Likert scale, with higher scores indicating greater symptom burden.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
PROMIS Self-Efficacy for Managing Emotions Short Form (8a)
大体时间:Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)

The PROMIS Self-Efficacy for Managing Emotions 8-item Short Form will be used to assess patient-reported confidence in managing negative emotions and emotional distress related to chronic illness. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater self-efficacy for managing emotions.

Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
PROMIS Self-Efficacy for Managing Symptoms Short Form (8a)
大体时间:Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)

The PROMIS Self-Efficacy for Managing Symptoms 8-item Short Form will be used to assess patient-reported confidence in managing symptoms and limiting their interference with daily life. PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater self-efficacy for managing symptoms.

Baseline (week 0), mid-point of intervention (week 5), post-intervention (week 11), and 1 month follow-up (week 15)
Functional Assessment of Cancer Therapy - Breast (FACT-B)
大体时间:Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The FACT-B will be used to assess patient-reported quality of life across physical, social/family, emotional, and functional domains, as well as breast cancer-specific concerns. Items are rated on a 5-point Likert scale (0 = Not at all to 4 = Very much) and summed to form subscale and total scores. Higher subscale and total scores indicate better quality of life.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
PROMIS Emotional Support
大体时间:Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)

The PROMIS Emotional Support (4a) Short Form will assess social support. The PROMIS scores are expressed as T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate greater access to social support networks.

Baseline (week 0), post-intervention (week 11), and 1 month follow-up (week 15)
Group Therapy Experience Scale
大体时间:Post-intervention (week 11)

The Group Therapy Experience Scale will measure perceived cohesion, self-disclosure, and satisfaction with group therapy. The 16 item scale uses a Likert scale with responses ranging from 1(strongly disagree) to 5(strongly agree). Higher scores indicate higher satisfaction with group therapy.

Post-intervention (week 11)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Kelly Hyland, PhD、Medical University of South Carolina

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月30日

初级完成 (估计的)

2027年4月30日

研究完成 (估计的)

2027年5月31日

研究注册日期

首次提交

2026年4月13日

首先提交符合 QC 标准的

2026年4月13日

首次发布 (实际的)

2026年4月20日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅